• Mylan Inc., of Pittsburgh, and Agila Specialities Global Pte. Ltd., of Bangalore, India, have had conditions on Mylan’s proposed acquisition of Agila imposed by the Federal Trade Commission (FTC), which is requiring the firms to divest 11 generic injectable drugs prior to the acquisition.